Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Citizens JMP analyst firm has reiterated its Market Outperform rating and $86.00 price target on CRISPR Therapeutics (NASDAQ:CRSP), representing significant upside from the current price of $43.19. According to InvestingPro data, analyst targets for the stock range from $32 to $268, reflecting the stock’s notable volatility. The decision comes as the company makes progress with its in-vivo therapeutic programs, which according to the firm have received minimal valuation contribution to date.
CRISPR Therapeutics recently released data from its CTX310 program, demonstrating dose-dependent decreases in ANGPTL3 protein levels. The single-dose treatment showed what Citizens JMP described as "best-in-class peak TG and LDL reductions" in cardiovascular applications. The company maintains a strong financial position, with InvestingPro analysis showing more cash than debt on its balance sheet and a healthy current ratio of 15.64.
The firm noted that competitor Verve Therapeutics is valued at over $1 billion for similar indications, suggesting potential upside for CRISPR Therapeutics as it advances its in-vivo pipeline.
Citizens JMP expects a first-in-human update from CTX320, the company’s second cardiovascular program targeting Lp(a), later this month.
The research firm’s analysis indicates CRISPR Therapeutics’ expanding portfolio beyond its initial focus areas could provide additional growth opportunities that are not yet reflected in the company’s current valuation.
In other recent news, CRISPR Therapeutics has announced the approval of several key proposals at its 2025 Annual General Meeting. Shareholders ratified the company’s financial statements for the year ended December 31, 2024, and endorsed the election of board members, including the chairman. In a strategic move, CRISPR Therapeutics has partnered with Sirius Therapeutics to develop SRSD107, a novel siRNA therapy targeting thromboembolic disorders, with the collaboration expected to reach pivotal trials next year. Citizens JMP has maintained its Market Outperform rating and $86 price target for CRISPR Therapeutics, highlighting the potential of the partnership with Sirius Therapeutics. Meanwhile, Clear Street has upgraded CRISPR Therapeutics’ stock from Hold to Buy, setting a new price target of $45, following positive first-quarter 2025 results. JMP analysts have reaffirmed their Market Outperform rating, noting promising data from CRISPR’s in-vivo programs, which include reductions in ANGPTL3 levels and cholesterol. These developments underscore CRISPR Therapeutics’ commitment to advancing its gene-editing therapies and expanding its pipeline with innovative treatments. The company reported a robust cash position of $1.86 billion, supporting its strategic initiatives and future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.